Hubro Therapeutics, a clinical stage company advancing a pipeline of proprietary peptide cancer vaccines, announces successful closing of a private placement that will allow the company to initiate clinical development of its lead product candidate FMPV-1 targeting TGFbR2 neo-antigen present in colorectal-, stomach and endometrial-cancer.
Hubro Therapeutics announced today that the company has raised 61,5 million NOK (≈6,5 mill.euro) in a heavily oversubscribed financing round backed by existing investors Jandersen Kapital, Investinor, RADFORSK Investeringsstiftelse, Algot Invest and others. The company is grateful for existing shareholders’ continued belief in the company. The company also welcomed new investors, most notably Canica Holding AG who was offered about fifty percent of the newly issued shares.
For more information, please contact:
Jon Amund Eriksen, CEO